Innoviva (INVA) Cash & Equivalents Growth (5y) (2014 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.35% |
| Dec 31, 2025 | 17.45% |
| Sep 30, 2025 | -0.11% |
| Jun 30, 2025 | -0.77% |
| Mar 31, 2025 | -1.94% |
| Dec 31, 2024 | 1.86% |
| Sep 30, 2024 | 8.55% |
| Jun 30, 2024 | 8.86% |
| Mar 31, 2024 | 22.31% |
| Dec 31, 2023 | 25.40% |
| Sep 30, 2023 | 29.93% |
| Jun 30, 2023 | 14.68% |
| Mar 31, 2023 | 39.63% |
| Dec 31, 2022 | 31.74% |
| Sep 30, 2022 | 16.79% |
| Jun 30, 2022 | 17.31% |
| Mar 31, 2022 | 6.29% |
| Dec 31, 2021 | 11.30% |
| Sep 30, 2021 | 7.71% |
| Jun 30, 2021 | -17.46% |
| Mar 31, 2021 | 13.26% |
| Dec 31, 2020 | 9.14% |
| Sep 30, 2020 | 43.50% |
| Jun 30, 2020 | 22.53% |
| Mar 31, 2020 | 20.05% |
| Dec 31, 2019 | 23.50% |
| Sep 30, 2019 | 7.66% |
| Jun 30, 2019 | -7.36% |
| Mar 31, 2019 | -12.26% |
| Dec 31, 2018 | -15.34% |
| Sep 30, 2018 | -22.32% |
| Jun 30, 2018 | -15.23% |
| Mar 31, 2018 | -36.65% |
| Dec 31, 2017 | -5.01% |
| Sep 30, 2017 | 4.28% |
| Jun 30, 2017 | -4.55% |
| Mar 31, 2017 | 62.03% |
| Dec 31, 2016 | 21.39% |
| Sep 30, 2016 | 8.24% |
| Jun 30, 2016 | 4.49% |
| Mar 31, 2016 | 0.52% |
| Dec 31, 2015 | -0.51% |
| Sep 30, 2015 | 4.53% |
| Jun 30, 2015 | 16.49% |
| Dec 31, 2014 | 15.28% |